Literature DB >> 22425256

ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling.

Cinzia Gellera1, Nicola Ticozzi, Viviana Pensato, Lorenzo Nanetti, Alessia Castucci, Barbara Castellotti, Giuseppe Lauria, Franco Taroni, Vincenzo Silani, Caterina Mariotti.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease mainly involving cortical and spinal motor neurons. Several studies indicated that intermediate CAG expansions in ataxin-2 gene (ATXN2) are associated with increased risk of ALS. We analyzed ATXN2 CAG repeats in 658 sporadic ALS patients (SALS), 143 familial ALS cases (FALS), 231 sporadic ataxic subjects, and 551 control subjects. The frequency of ATXN2 alleles with 27-30 repeats was similar in SALS and control subjects. Fifteen SALS subjects carried ≥ 31 CAG repeats. This difference was statistically significant (p = 0.0014). No alleles with ≥ 34 CAG were found. In FALS, the distribution of ATXN2 alleles was similar to control subjects. Our results further contributed in refining CAG-repeat range significantly associated with sporadic ALS. Literature data and our findings indicate that only alleles with ≥ 31 CAG may represent low-penetrance disease/susceptibility alleles associated with variable neurodegenerative phenotypes, including cerebellar ataxia, parkinsonism, and ALS. Overlapping phenotypes should be considered in genetic testing and counseling, both for patients and at-risk family members.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425256     DOI: 10.1016/j.neurobiolaging.2012.02.004

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  11 in total

1.  Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2.

Authors:  Sirinan Tazen; Karla Figueroa; Justin Y Kwan; Jill Goldman; Ann Hunt; Jacinda Sampson; Laurie Gutmann; Stefan M Pulst; Hiroshi Mitsumoto; Sheng-Han Kuo
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

Review 2.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

3.  Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers.

Authors:  Marka van Blitterswijk; Bianca Mullen; Michael G Heckman; Matthew C Baker; Mariely DeJesus-Hernandez; Patricia H Brown; Melissa E Murray; Ging-Yuek R Hsiung; Heather Stewart; Anna M Karydas; Elizabeth Finger; Andrew Kertesz; Eileen H Bigio; Sandra Weintraub; Marsel Mesulam; Kimmo J Hatanpaa; Charles L White; Manuela Neumann; Michael J Strong; Thomas G Beach; Zbigniew K Wszolek; Carol Lippa; Richard Caselli; Leonard Petrucelli; Keith A Josephs; Joseph E Parisi; David S Knopman; Ronald C Petersen; Ian R Mackenzie; William W Seeley; Lea T Grinberg; Bruce L Miller; Kevin B Boylan; Neill R Graff-Radford; Bradley F Boeve; Dennis W Dickson; Rosa Rademakers
Journal:  Neurobiol Aging       Date:  2014-05-02       Impact factor: 4.673

4.  Association of ATXN2 intermediate-length CAG repeats with amyotrophic lateral sclerosis correlates with the distributions of normal CAG repeat alleles among individual ethnic populations.

Authors:  Hiroya Naruse; Takashi Matsukawa; Hiroyuki Ishiura; Jun Mitsui; Yuji Takahashi; Hiroki Takano; Jun Goto; Tatsushi Toda; Shoji Tsuji
Journal:  Neurogenetics       Date:  2019-03-07       Impact factor: 2.660

5.  Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders.

Authors:  Serena Lattante; Stéphanie Millecamps; Giovanni Stevanin; Sophie Rivaud-Péchoux; Carine Moigneu; Agnès Camuzat; Sandra Da Barroca; Emeline Mundwiller; Philippe Couarch; François Salachas; Didier Hannequin; Vincent Meininger; Florence Pasquier; Danielle Seilhean; Philippe Couratier; Véronique Danel-Brunaud; Anne-Marie Bonnet; Christine Tranchant; Eric LeGuern; Alexis Brice; Isabelle Le Ber; Edor Kabashi
Journal:  Neurology       Date:  2014-08-06       Impact factor: 9.910

6.  Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis.

Authors:  Annalese G Neuenschwander; Khanh K Thai; Karla P Figueroa; Stefan M Pulst
Journal:  JAMA Neurol       Date:  2014-12       Impact factor: 18.302

Review 7.  Drosophila as an In Vivo Model for Human Neurodegenerative Disease.

Authors:  Leeanne McGurk; Amit Berson; Nancy M Bonini
Journal:  Genetics       Date:  2015-10       Impact factor: 4.562

Review 8.  The epidemiology and genetics of Amyotrophic lateral sclerosis in China.

Authors:  Xiaolu Liu; Ji He; Fen-Biao Gao; Aaron D Gitler; Dongsheng Fan
Journal:  Brain Res       Date:  2018-03-01       Impact factor: 3.610

Review 9.  Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS--a systematic review and meta-analysis of observational studies.

Authors:  Ming-Dong Wang; James Gomes; Neil R Cashman; Julian Little; Daniel Krewski
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

10.  De novo mutations in ataxin-2 gene and ALS risk.

Authors:  José Miguel Laffita-Mesa; Jorge Michel Rodríguez Pupo; Raciel Moreno Sera; Yaimee Vázquez Mojena; Vivian Kourí; Leonides Laguna-Salvia; Michael Martínez-Godales; José A Valdevila Figueira; Peter O Bauer; Roberto Rodríguez-Labrada; Yanetza González Zaldívar; Martin Paucar; Per Svenningsson; Luís Velázquez Pérez
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.